Table 1 Patient characteristics (n = 68)
From: Prognostic factors of brain metastases from colorectal cancer
Characteristic | Category | No. of patients (%) |
|---|---|---|
Sex | Male | 43 (63%) |
Female | 25 (37%) | |
Age at the time of brain metastases (years) | < 65 | 33 (49%) |
≥65 | 35 (51%) | |
Location of primary tumor | Colon | 42 (62%) |
Rectum | 26 (38%) | |
Time interval from diagnosis of primary tumor to brain metastases | Synchronous | 14 (21%) |
Metachronous | 54 (79%) | |
Karnofsky performance status score | ≥70 | 27 (40%) |
< 70 (≤60) | 41 (60%) | |
Presence of extracranial metastases | Absent (Brain only) | 14 (21%) |
Present (Brain and other sites) | 54 (79%) | |
Control of primary tumor | Controlled | 57 (84%) |
Uncontrolled | 11 (16%) | |
Maximum diameter of brain metastases | < 3 cm | 40 (59%) |
≥3 cm | 28 (41%) | |
Number of brain metastases | Limited: 1–3 | 42 (62%) |
Multiple: ≥4 | 26 (38%) | |
Interval from diagnosis of primary tumor to brain metastases | < 12 months | 17 (25%) |
≥12 months | 51 (75%) | |
Location of brain lesions | Supratentorial | 39 (57%) |
Infratentorial | 11 (16%) | |
Both | 18 (27%) | |
History of systemic chemotherapy before diagnosis of brain metastases | None | 22 (32%) |
Fluoropyrimidine only | 13 (19%) | |
Fluoropyrimidine + oxaliplatin | 6 (9%) | |
Fluoropyrimidine + irinotecan | 6 (9%) | |
Fluoropyrimidine + oxaliplatin + irinotecan | 21 (31%) |